The broad expression of the insulin receptor suggests that the spectrum of insulin function has not been fully described. A cell type expressing this receptor is the osteoblast, a bone-specific cell favoring glucose metabolism through a hormone, osteocalcin, that becomes active once uncarboxylated. We show here that insulin signaling in osteoblasts is necessary for whole-body glucose homeostasis because it increases osteocalcin activity. To achieve this function insulin signaling in osteoblasts takes advantage of the regulation of osteoclastic bone resorption exerted by osteoblasts. Indeed, since bone resorption occurs at a pH acidic enough to decarboxylate proteins, osteoclasts determine the carboxylation status and function of osteocalcin. Accordingly, increasing or decreasing insulin signaling in osteoblasts promotes or hampers glucose metabolism in a bone resorption-dependent manner in mice and humans. Hence, in a feedforward loop, insulin signals in osteoblasts activate a hormone, osteocalcin, that promotes glucose metabolism.
INTRODUCTION
Bone is a multitasking tissue with mechanical, hematopoietic, and metabolic functions that result from the tight interplay between two bone-specific cell types, the osteoblast and the osteoclast. Bone also emerged recently as an endocrine organ regulating glucose metabolism (Fukumoto and Martin, 2009 ), a function that has been ascribed to date only to the osteoblast. The intricacy existing between osteoblasts and osteoclasts raises the prospect, however, that the osteoclast may contribute to the endocrine role of the skeleton.
Bone uses the osteoblast-specific secreted molecule osteocalcin to favor glucose homeostasis. Circulating osteocalcin exists in two forms, carboxylated on 3 glutamate residues or undercarboxylated; the latter form being able to enhance insulin secretion by b-cells, insulin sensitivity and energy expenditure (Lee et al., 2007) . Osteocalcin (Ocn), however, is not the only gene expressed in osteoblasts affecting glucose homeostasis. Esp, a gene encoding an intracellular tyrosine phosphatase called OST-PTP exerts, through its osteoblast expression, metabolic functions opposite to those of osteocalcin (Lee et al., 2007) . Genetic and biochemical evidence show that Esp acts upstream of Ocn to inhibit its metabolic function. For instance, the metabolic phenotype of Esp À/À mice is fully corrected by removing one allele of Ocn even though Ocn +/À mice have no metabolic phenotype, and the fraction of undercarboxylated osteocalcin is significantly higher in Esp À/À than in wild-type (WT) mouse serum.
The role of the osteoblast in regulating glucose metabolism revealed by these and other findings (Rached et al., 2010a; Yoshizawa et al., 2009 ) raises questions. The first one is to explain how OST-PTP, an intracellular tyrosine phosphatase, can influence the carboxylation and function of a secreted molecule like osteocalcin. A second issue is to provide evidence that the same bone-dependent regulation of glucose metabolism exists in humans since ESP is a pseudogene in this species (Cousin et al., 2004) . A third question of physiological nature looming beyond these observations is whether insulin, in a feedback loop, influences osteocalcin synthesis and/or activity.
The insulin receptor is a tyrosine kinase whose activity must be tightly regulated since it can be activated in the absence of ligand (Kasuga et al., 1983) . Receptor tyrosine kinases are often inhibited by protein tyrosine phosphatases (PTPs) (Schlessinger, 2000) and PTP1B, which dephosphorylates the insulin receptor, is a major regulator of insulin signaling in hepatocytes and myocytes (Delibegovic et al., 2007 (Delibegovic et al., , 2009 . The fact that OST-PTP is a tyrosine phosphatase raises the testable hypothesis that the insulin receptor is one of its substrates.
Our understanding of insulin signaling in various tissues has been profoundly altered by the analysis of mutant mouse strains lacking the insulin receptor in only one cell type (Bluher et al., 2002; Bruning et al., 1998; Konner et al., 2007; Kulkarni et al., 1999; Michael et al., 2000) . Surprisingly, these studies failed to demonstrate a major influence of insulin signaling in the control of whole-body glucose homeostasis in two classical insulin target tissues, muscle, and white fat (Bluher et al., 2002; Bruning et al., 1998 ). An implication of these observations is that insulin may act in additional organs in order to maintain glucose homeostasis. This hypothesis is consistent with the fact that the insulin receptor is expressed in many cell types where its functions have not yet been analyzed. This is particularly relevant to the osteoblast since it expresses the insulin receptor and regulates insulin secretion ( Figure 1A ) (Lee et al., 2007) .
Here, we show that the insulin receptor is a substrate of OST-PTP and PTP1B in mouse and human osteoblasts, respectively. As a result, insulin signaling in osteoblasts enhances osteocalcin activity and impacts glucose homeostasis by promoting the ability of osteoblasts to enhance bone resorption. Indeed, because the acid pH in the resorption lacuna allows protein decarboxylation it is ultimately the activity of the osteoclast that determines the carboxylation status and function of osteocalcin secreted by the osteoblast. These results reveal a pH-dependent mechanism of activation for a hormone and identify insulin signaling in osteoblasts as a critical link between bone remodeling and energy metabolism.
RESULTS

The Insulin Receptor Is a Substrate of OST-PTP in Mouse Osteoblasts
In order to define the mechanism whereby Esp affects osteocalcin carboxylation, we asked whether osteocalcin and/or enzymes required for its carboxylation, g-carboxylase and Vkorc1 (Sadler, 2004) , are phosphorylated on tyrosine residues and could be substrates of OST-PTP. We failed to detect tyrosine phosphorylation of these enzymes or of an osteocalcin peptide including all tyrosine residues of this molecule (Figures S1A-S1C available online). We also failed to detect physical interactions between osteocalcin, g-carboxylase, or Vkorc1, and OST-PTP ( Figures S1D-S1F ). Although these negative See also Figure S1 .
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results must be interpreted cautiously, they imply that OST-PTP does not affect osteocalcin carboxylation by acting directly on osteocalcin, g-carboxylase, or Vkorc1. To pursue our search, we used substrate trapping, an assay using phosphatase domains in which a single amino acid substitution abrogates their catalytic activity, not their ability to recognize substrates (Flint et al., 1997) .
We used OST-PTP active phosphatase domain (Chengalvala et al., 2001 ) to test whether the insulin receptor (InsR) was a substrate of OST-PTP for the following reasons. First, dephosphorylation of the InsR by another tyrosine phosphatase, PTP1B, regulates insulin signaling in other cell types (Delibegovic et al., 2007; Delibegovic et al., 2009 ). Second, OST-PTP has homology in its catalytic domain to phosphatases dephosphorylating the InsR ( Figure S1G ). Third, the InsR is abundant in osteoblasts and treatment of osteoblasts with insulin increases phosphorylation of the InsR and its downstream targets AKT, GSK3b, FoxO1 and p70S6K ( Figure 1A and Figure S1H ). Fourth, InsR phosphorylation increased in bone in a time-dependent manner following insulin injection in vivo ( Figure 1B ). Furthermore, we reasoned that if osteoblasts favor glucose homeostasis insulin signaling should influence osteoblast biology.
The InsR interacted with a mutated form of OST-PTP or of PTP1B, a positive control, but not with negative controls such as wild-type (WT) OST-PTP, PTP1B or glutathione S-transferase (GST); InsR interaction with OST-PTP was competed by increasing concentrations of orthovanadate, OST-PTP interacted with InsR in cells following insulin treatment only, and did not interact with an unrelated tyrosine kinase receptor ( Figures 1C-1E ). Furthermore, WT OST-PTP dephosphorylated in vitro InsR while a mutant form of OST-PTP lacking its phosphatase activity did not (Figures 1F and 1G) . Consistent with these results, phosphorylation of InsR on tyrosines 1150 and 1151 and of FoxO1, a target of insulin signaling (Puigserver et al., 2003) , was increased in Esp À/À osteoblasts ( Figure 1H and Figures S1I and S1J). These experiments provide congruent biochemical evidence indicating that InsR is a substrate of OST-PTP in mouse osteoblasts.
Insulin Signaling in Osteoblasts Is a Determinant of Whole-Body Glucose Metabolism
That insulin signaling in osteoblasts is regulated by OST-PTP, a phosphatase affecting glucose metabolism, implies that it also influences this process. To address this question, we generated osteoblast-specific Insulin Receptor (InsR)-deficient mice (InsR osb À/À mice) by crossing a1(I)collagen-Cre transgenic mice, which delete genes in osteoblasts only (Dacquin et al., 2002) , with mice harboring a floxed allele of InsR ( Figures S2A-S2C ). Western blot analysis of osteoblasts showed at least 60% deletion of the InsR in osteoblasts but not in liver, pancreas, white adipose tissue, muscle, and brain of InsR osb À/À mice ( Figures S2D-S2F ).
InsR osb À/À mice were born at the expected Mendelian ratio and at 8 weeks of age presented a significant elevation of blood glucose in the fed state and a significant reduction of serum insulin levels in the fasted or fed state, glucagon levels being unaffected (Figures 2A and 2B and Figure S2G) . A glucose-stimulated insulin secretion (GSIS) test verified that insulin secretion was decreased in InsR osb À/À mice ( Figure 2C ). There was also a decrease in the number of islets, islet size, b-cell mass, b-cell proliferation and insulin content in InsR osb À/À compared to control pancreata ( Figure 2D ). As a result of this decrease in insulin secretion a glucose tolerance test (GTT) demonstrated glucose intolerance in InsR osb À/À mice ( Figure 2E and Figure S2H ). Insulin tolerance, as measured by an insulin tolerance test (ITT), was also significantly reduced in InsR osb À/À compared to control mice ( Figure 2F and Figure S2I ). Hence, analysis of InsR osb À/À mice revealed that insulin signaling in osteoblasts contributes to whole-body glucose homeostasis by increasing b-cell proliferation and insulin secretion and energy expenditure ( Figure 2H and Figures S2J and S2K ). Insulin often transmits its signal by inhibiting FoxO1 activity. Since FoxO1 affects glucose homeostasis through its expression in osteoblasts (Rached et al., 2010a) Figures 3F-3H ). These two experiments provide genetic evidence that a function of insulin signaling in osteoblasts is to favor osteocalcin metabolic activity ( Figure 3I ). That reducing insulin signaling in osteoblasts corrected the enhanced glucose and insulin tolerance of Esp À/À mice was important in its own right, because it indicated that the metabolic phenotype of Esp À/À mice is secondary to an increase in insulin signaling in osteoblasts. This contention is supported by the increased phosphorylation of the InsR in Esp À/À osteoblasts ( Figure 1H ). Thus, in subsequent experiments studying insulin signaling in osteoblasts, we relied on both loss-(InsR osb À/À ) and gain-of-function (Esp À/À ) models.
Insulin Signaling in Osteoblasts Inhibits Osteocalcin Carboxylation
To ascertain that insulin signaling in osteoblasts regulates osteocalcin activity, we developed a dual ELISA quantifying the ratio between undercarboxylated, i.e., active (GLU), and carboxylated, i.e., inactive (GLA), circulating osteocalcin ( Figures S3A-S3E ). This ELISA detected an increase in undercarboxylated osteocalcin in Esp À/À mice, which harbor an increase in insulin signaling in osteoblasts ( Figure 1H ) but not in Esp
;InsR osb +/À mice that do not ( Figure 3J ). In contrast, it showed that undercarboxylated osteocalcin levels were decreased when insulin signaling is impaired in osteoblasts (InsR osb À/À mice), even though Ocn expression and serum levels were not affected (Figure 3J and Figures S3F and S3G) . A decrease in undercarboxylated osteocalcin was also observed in Ocn +/À ;InsR osb +/À mice that display a glucose intolerance similar to the one of the Ocn À/À and InsR osb À/À mice ( Figure 3J and Figure S3H ). These measurements of undecarboxylated osteocalcin in various mutant mouse strains along with the genetic evidence presented above indicate that insulin signaling in osteoblasts inhibits osteocalcin carboxylation, i.e., is a positive regulator of its metabolic activity.
Insulin Signaling in Osteoblasts Favors Bone Resorption
In a separate line of work, we noticed a marked decrease in the serum level of CTx, a marker of bone resorption, in InsR osb 
See also Figure S2 .
mice, whereas this parameter was increased in Esp À/À mice ( Figure 4A ). This data suggested that insulin signaling in osteoblasts favors bone resorption. Although not the focus of this study, bone formation parameters were severely decreased in InsR osb
mice; as a result, these mice had a low bone mass ( Figure S4A ).
To prove that insulin signaling in osteoblasts affects bone resorption, we used a coculture assay of osteoblasts and osteoclasts (Takahashi et al., 1988) . When cocultured with WT osteoblasts, WT osteoclast precursor cells differentiated and formed resorption pits. When WT osteoclast precursor cells See also Figure S3 .
were cocultured with InsR À/À osteoblasts, the area covered by resorption pits was significantly decreased, whereas it increased 50% when cocultured with Esp À/À osteoblasts ( Figure 4B ). That the number of osteoclasts was unaffected whether we used Esp À/À or InsR À/À osteoblasts ( Figure 4B ) is consistent with the notion that insulin signaling in osteoblasts promotes only the function of osteoclasts. We next studied expression of genes influencing bone resorption in osteoblasts and noticed that expression of Osteoprotegerin (Opg), a gene encoding a decoy receptor for RANKL and a negative regulator of osteoclast function (Teitelbaum See also Figure S4 .
decreased 50% in Esp À/À osteoblasts; its secretion followed the same pattern ( Figures 4C-4E ). That insulin treatment of WT but not of InsR À/À osteoblasts decreased Opg expression and secretion verified that it is an insulin target gene in osteoblasts ( Figure 4E ). To demonstrate that a moderate increase in OPG secretion inhibits the activity rather than the differentiation of osteoclasts, we cultured osteoclast progenitor cells in the presence of increasing amount of OPG (0-90 ng/ml). Low amounts of OPG in the culture medium decreased the surface covered by resorption pits but not the osteoclasts number ( Figure 4F ).
Multiple evidences indicated that insulin signaling in osteoblasts favors bone resorption by inhibiting FoxO1. First, Opg expression was increased 2-fold in ROS17/2.8 osteoblastic cells overexpressing FoxO1 ( Figure 4G ). Second, siRNA-mediated downregulation of FoxO1 decreased Opg expression and secretion in mouse osteoblasts ( Figure 4H and Figure S4B) . Third, the increase in bone resorption noted in FoxO1 obs À/À mice (Rached et al., 2010b) could be traced to a decrease in Opg expression in bone ( Figure 4I ). Fourth, removing one allele of FoxO1, in osteoblasts only, from InsR osb À/À mice normalized bone resorption ( Figure 4J ).
Insulin Signaling in Osteoblasts Promotes the Osteoclasts Ability to Acidify the Bone Extracellular Matrix Next, we sought to identify Opg-dependent molecular events taking place in osteoclasts under the control of insulin signaling in osteoblasts. Expression of CathepsinK (Ctsk) and Tcirg1, two genes implicated in bone resorption, was decreased in InsR osb À/À and increased in Esp À/À bones ( Figure 4K ). Ctsk and Tcirg1 expression was also decreased in osteoclasts obtained following coculture of WT osteoclast precursors cells with InsR À/À osteoblasts ( Figure 4L ). For the rest of this study we focused on Tcirg1, a gene encoding a vacuolar proton pump subunit essential for acidification of the bone extracellular matrix (ECM), precisely because acidification of the bone ECM is a prerequisite for bone resorption (Teitelbaum and Ross, 2003) . Taken together, the biochemical, molecular, and genetic evidence presented above indicates that insulin signaling in osteoblasts decreases Opg expression and the Opg/Rankl ratio ( Figure 4M) ; this results in an increase in Tcirg1 expression, in ECM acidification, and in bone resorption.
Bone Resorption as a Means to Decarboxylate Osteocalcin
An acid pH can decarboxylate proteins (Engelke et al., 1991) , and this raises the prospect that bone resorption, which occurs at an acid pH, can decarboxylate osteocalcin in vivo.
To verify that an acid pH could decarboxylate and activate osteocalcin, equal amounts of carboxylated osteocalcin were incubated for 2 weeks at 37 C in solutions buffered at either pH 7.5 or pH 4.5, the latter being the pH present in the resorption lacunae (Silver et al., 1988 ). Each osteocalcin solution was then analyzed by high-resolution mass spectrometry. This revealed a peak at m/z 1325.103 (+4) corresponding to a form of osteocalcin in which all three glutamic residues are carboxylated (molecular weight: 5296.42 Da) and another peak at m/z 1314.108 (+4) corresponding to an osteocalcin form in which one of the three glutamic residues was not carboxylated (molecular weight: 5252.43 Da) ( Figure 5A ). The mass difference between these two forms is 43.9 Da, which corresponds to one carboxylation modification.
Importantly, the ratio of undercarboxylated to fully carboxylated osteocalcin was significantly increased when osteocalcin was incubated at pH 4.5 ( Figure 5A and Figure S5A ). Tandem mass spectrometry analysis of trypsin-digested samples demonstrated that the presence of a GLU residue at position 13 was increased more than 2-fold upon incubation at pH 4.5 ( Figure 5B ), thus suggesting that this residue is highly susceptible to decarboxylation. We also assessed the metabolic activity of these two preparations of osteocalcin. When rat insulinoma INS-1 cells were treated with carboxylated (pH 7.5) or undercarboxylated (pH 4.5) osteocalcin, only the latter form could increase insulin secretion to the same extent as recombinant uncarboxylated osteocalcin used as a positive control (Ferron et al., 2008) (Figure 5C ).
Given these results, we cultured osteoclast precursor cells in the presence or absence of RANKL on bovine cortical bone slides devitalized to exclude any endogenous osteoblastic activity. Two days after osteoclasts were identifiable, total, carboxylated, and undercarboxylated osteocalcin were measured. When osteoclast differentiation had been triggered by RANKL, the levels of total and undercarboxylated (GLU) osteocalcin were increased, while that of carboxylated (GLA) osteocalcin was decreased. As a result, there was a 2-fold increase in the GLU/GLA ratio ( Figures 5D and 5E) . Thus, the resorptive activity of osteoclasts suffices to activate osteocalcin.
The Osteoclast Ability to Acidify the Bone ECM Favors Glucose Homeostasis
Given the role of osteocalcin in glucose metabolism, we next asked whether the osteoclasts ability to activate osteocalcin affects glucose metabolism. For that purpose we analyzed oc/oc mice harboring a loss-of-function mutation in Tcirg1 resulting in osteopetrosis (Scimeca et al., 2000) . The level of undercarboxylated osteocalcin was decreased 30% in oc/oc compared to WT serum ( Figure 5F ). Accordingly, conditioned medium of oc/oc calvaria cultures did not stimulate insulin secretion by INS-1 cells ( Figure 5G ). Hence, in oc/oc mice whose osteoclasts cannot acidify the bone ECM, circulating osteocalcin is metabolically inactive.
Importantly, for our purpose, oc/oc mice were also glucose intolerant ( Figures 5H and 5I ) with a marked decrease in serum insulin levels, pancreas insulin content, and Insulin expression in pancreas (Figures 5J-5L ). To determine whether this phenotype was secondary to a function of Tcirg1 in osteoclasts, we transplanted oc/oc fetal liver hematopoietic stem cells into WT irradiated mice. Transplantation of mutant hematopoietic stem cells resulted in high bone mass in WT recipient animals because their osteoclasts could not form resorption pits ( Figure 5M and Figures S5B-S5F ). Fasting glucose blood levels were increased while serum insulin levels in fasted and fed states were decreased in mice transplanted with oc/oc cells ( Figures 5N  and 5O) . A GSIS test demonstrated a defect in insulin secretion in these mice, whereas a GTT showed glucose intolerance ( Figures 5P-5R) . Energy expenditure was also decreased in WT mice transplanted with oc/oc cells ( Figure 5S and Figures  S5G and S5H ). As expected, in mice transplanted with oc/oc cells, there was a significant decrease in serum undercarboxylated osteocalcin while the total osteocalcin level was unchanged ( Figure 5T and Figure S5I ). These results demonstrate that the osteoclasts ability to acidify the bone ECM is both necessary and sufficient to activate osteocalcin and to influence whole-body glucose metabolism.
Insulin Signaling in Osteoblasts Favors Glucose Homeostasis in a Bone Resorption-Dependent Manner
The observations presented above beg the following question: Is it because it favors bone resorption that insulin signaling in osteoblasts promotes glucose homeostasis? In (C), **p < 0.01 and ***p < 0.001 versus control and GLA-OCN pH7.5 (ANOVA). In (D), (E), and (G), *p < 0.05 and **p < 0.01 versus control and/or medium (ANOVA). In (F), (I-O), and (R-T), *p < 0.05 and **p < 0.01 versus WT (t test). In (H), (P), and (Q), *p < 0.05 and **p < 0.01 versus WT (ANOVA). See also Figure S5 .
To determine whether the influence of insulin signaling in osteoblasts on glucose metabolism depends on the osteoclasts ability to acidify the bone ECM, we generated mice lacking one allele of InsR in osteoblasts and harboring one oc allele (InsR osb +/À ;oc/+ mice). In these mutant mice, osteocalcin undercarboxylation was markedly decreased ( Figure 6A) ; as a result of this shift toward decreased osteocalcin activity, insulin secretion, glucose, and insulin tolerance were impaired in InsR osb +/ À ;oc/+ but not in InsR osb +/À or oc/+ mice ( Figures 6B-6D and Figure S6A ). These data genetically link insulin signaling in osteoblasts, bone resorption, and whole-body glucose homeostasis. If insulin signaling in osteoblasts promotes glucose homeostasis in a bone resorption-dependent manner, then inhibiting bone resorption in a model of increased insulin signaling in osteoblasts, such as the Esp À/À mice, should correct their metabolic phenotypes. Indeed, and unlike Esp À/À mice, Esp
;oc/+ mice had normal bone resorption, normal osteocalcin carboxylation status ( Figures 6E and 6F) , normal insulin secretion, normal glucose, and insulin tolerance ( Figures 6G-6I and Figure S6B ). Likewise, when we treated Esp À/À mice with alendronate, an inhibitor of osteoclast activity (Fisher et al., 1999) , osteocalcin carboxylation, insulin secretion, glucose, and insulin tolerance were normalized ( Figures 6J-6N and Figure S6C ). Lastly, if insulin signaling in osteoblasts promotes glucose metabolism by increasing bone resorption, stimulating bone resorption should rescue, at least partially, glucose intolerance in WT mice. To test this contention, we fed WT mice a high-fat diet and treated them with RANKL or GST as a negative control. As expected, RANKL increased bone resorption parameters ( Figures S6D and S6E ). This increase in bone resorption led to a 3-fold increase in serum levels of undercarboxylated osteocalcin ( Figure 6O ). RANKL-treated mice fed a high-fat diet secreted more insulin, were significantly less glucose intolerant, more insulin tolerant and less fat than GST-treated mice ( Figures 6P-6S and Figure S6F) . These three experiments demonstrate that insulin signaling in osteoblasts cannot affect osteocalcin activity and glucose metabolism if bone resorption is impaired.
Insulin Signaling in Human Osteoblasts, Bone Resorption, Osteocalcin Activity, and Glucose Homeostasis Clinical studies indicate that osteocalcin is involved in glucose homeostasis in humans (Hwang et al., 2009; Kanazawa et al., 2009; Pittas et al., 2009 ). However, since ESP is a pseudogene in humans (Cousin et al., 2004) osteocalcin activity must be regulated by another phosphatase. The identification of InsR as a substrate of OST-PTP provided a way to address this question.
We asked whether PTP1B, a tyrosine phosphatase able to dephosphorylate INSR, was present in human osteoblasts. PTP1B was markedly more abundant in human than in mouse osteoblasts and decreasing its expression in human osteoblasts increased INSR and FOXO1 phosphorylation and decreased OPG expression (Figures 7A-7D) . Conversely, siRNA-mediated knockdown of INSR in human osteoblasts decreased FOXO1 phosphorylation and increased OPG expression ( Figures 7D  and 7E ). Finally, PTP1B could trap INSR in human osteoblasts ( Figure 7F ). Thus, insulin signaling in human osteoblasts is regulated by a tyrosine phosphatase and favors bone resorption.
The observations made in mice imply that patients harboring a defect in bone resorption (osteopetrosis) should have low serum undercarboxylated osteocalcin and serum insulin levels. We tested this contention by analyzing patients with an autosomal dominant form of osteopetrosis. Three patients had a missense mutation in ClCN7, a gene required for acid secretion in the resorption lacuna (Schaller et al., 2005) ; for the others, although no genetic defect could be identified, a decrease of acidification ability was demonstrated in osteoclasts cultured ex vivo in presence of LysoSensor fluorescent pH indicators ( Figures S7A and S7B) . Circulating undercarboxylated osteocalcin was significantly decreased in all patients, as were serum insulin levels measured after feeding ( Figure 7G ). These data support the notion that osteocalcin activity is determined in humans, in part, by bone resorption, an aspect of bone remodeling regulated by insulin signaling in osteoblasts.
DISCUSSION
This study demonstrates that insulin signaling in osteoblasts is a significant determinant of whole-body glucose homeostasis. Taking full advantage of the interplay between osteoblasts and osteoclasts characterizing bone remodeling, insulin signaling in osteoblasts achieves this function by favoring osteocalcin decarboxylation ( Figure 7H ). Thus, this study identifies insulin as a key molecular link between bone remodeling and energy metabolism.
Insulin Signaling in Osteoblasts and Glucose Homeostasis
Insulin signaling and functions in various tissues have been extensively studied in vivo in the last 10 years using mutant mouse strains lacking the insulin receptor in only one cell type. These studies have redefined the respective contributions of various cell types to whole-body glucose homeostasis. For instance, they showed that insulin signaling in b-cells is needed for insulin secretion and, as expected, insulin signaling in hepatocytes is needed for insulin sensitivity (Kulkarni et al., 1999; Michael et al., 2000) . In contrast, deletion of this receptor in white adipose tissue (WAT) resulted in an improvement of glucose metabolism (Bluher et al., 2002) . Taken together these various studies imply that insulin exerts yet to be identified functions in other tissues, an idea congruous with the fact that the insulin receptor is expressed in many cell types where its function has not been studied yet.
In agreement with this hypothesis, we show here, through the analysis of both loss-and gain-of-function models, that insulin signaling in osteoblasts influences whole-body glucose homeostasis by promoting insulin secretion. To the best of our knowledge osteoblasts and hepatocytes are the only cell types in which disrupting insulin signaling hampers glucose metabolism in mice fed a normal diet.
Insulin Signaling in Osteoblasts, Osteocalcin Activation, and Bone Resorption One issue surrounding osteocalcin biology has been elucidating how the intracellular phosphatase OST-PTP could favor carboxylation. Here, we identify the insulin receptor as a bona fide ;oc/+, and oc/+ (ANOVA). In (J)-(N), *p < 0.05 and **p < 0.01 versus WT and Esp À/À +Alend (ANOVA). In (O) and (S), *p < 0.05 and **p < 0.01 versus GST group (t test). In (P)-(R), *p < 0.05 and **p < 0.01, and ***p < 0.001 versus normal diet and GST groups (ANOVA). See also Figure S6 .
substrate of OST-PTP. This finding means that the metabolic phenotype of the OST-PTP-deficient mice characterized by improved whole-body glucose homeostasis (Lee et al., 2007) is due to an increase in insulin signaling in osteoblasts. More importantly, since OST-PTP regulates osteocalcin function these results also placed de facto insulin signaling in osteoblasts upstream of osteocalcin. To increase osteocalcin bioactivity insulin signaling in osteoblasts acts in a ricocheting manner using the huge amount of osteocalcin stored in the bone ECM and the interplay between osteoblasts and osteoclasts. Specifically, it takes advantage of the ability of the osteoblast to promote bone resorption. Since an acid pH is the only known chemical condition allowing protein decarboxylation (Engelke et al., 1991) , bone resorption, which occurs at pH 4.5, provides an ideal setting to decarboxylate and activate osteocalcin ( Figure 7H ).
The positive feedback loop existing between insulin signaling in osteoblasts and osteocalcin functions implies that negative regulators of this process may also exist. Leptin, another hormone exerting a major influence on energy metabolism, is one of them and does so also by modulating Esp expression . Thus, these studies highlight the unexpected importance of Esp in orchestrating the endocrine function of bone.
Another issue about osteocalcin biology has been to provide evidence that it has the same function in humans. Several arguments indicate that it is the case. First, the tyrosine phosphatase PTP1B fulfills in human osteoblasts the function that OST-PTP fulfills in mouse osteoblasts. Second, insulin signaling in human osteoblasts regulates OPG expression as it does in mouse osteoblasts. Third, osteopetrotic patients and mice display the same increase in osteocalcin carboxylation and decrease in insulin blood levels. These results support a growing number of observations linking osteocalcin or warfarin, a compound decreasing its carboxylation, to the regulation of glucose homeostasis in humans (Hwang et al., 2009; Kanazawa et al., 2009; Pittas et al., 2009; Scheen, 2005) . The notion that hampering bone resorption has deleterious consequences on glucose homeostasis is medically important since most drugs used to treat osteoporosis target this aspect of bone remodeling. Specifically, fasting plasma glucose levels are elevated in osteoporotic women treated with drugs inhibiting bone resorption and serum undercarboxylated osteocalcin levels are positively correlated with bone resorption in healthy women (Kaji et al., 2009; Yamauchi et al., 2010) .
Lastly, this work expands the relationship existing between bone remodeling and energy metabolism (Karsenty, 2006) and raises the testable hypothesis that the skeleton may exert additional endocrine influences on other, yet to be identified, physiological functions.
EXPERIMENTAL PROCEDURES
Mice Generation
Generation of Esp À/À (C57BL/6J;129/Sv), Ocn À/À (C57BL/6J;129/Sv), and
FoxO1 obs À/À (C57BL/6J;BALB/c) mice was reported (Dacquin et al., 2004; Ducy et al., 1996; Rached et al., 2010a) . InsR obs À/À mice were generated by intercrossing the progeny of crosses between InsR flox/flox mice, that harbor LoxP sites within introns 3 and 4 ( Figure S2A ), and a1(I)collagen-Cre transgenic mice (Dacquin et al., 2002) . oc/+ mice (C57BL/6J;C3H) were obtained from The Jackson Laboratory. Figures S6B-S6E ).
Metabolic Studies and Bioassays
Glucose tolerance test (GTT), glucose stimulated insulin secretion (GSIS), insulin tolerance test (ITT), pancreas insulin content, histology, and high-fat diet studies were performed as described (Lee et al., 2007) . ELISA were used to measure mouse/human insulin (Mercodia), plasma glucagon (ALPCO), mouse CTx (RatLaps, IDS), bovine/human osteocalcin carboxylation ratios (Takara), human TRAP (Bone TRAP Assay, IDS) and human CTx (Serum Crosslaps, IDS).
Biochemistry and Gene Expression Studies
A complete description of all biochemical experiments is available as Extended Experimental Procedures. All antibodies were obtained from Cell Signaling Technology, with the exception of anti-PTP1B (R&D), anti-FLAG, and anti-b-actin (Sigma). RNA isolation, cDNA preparation, and real-time PCR analyses were carried out following standard protocols. Substratetrapping was conducted as described (Flint et al., 1997) . Briefly, extracts from pervanadate-treated cells were incubated in the presence of GST recombinant protein and washed four times with lysis buffer. For in vitro dephosphorylation assays, ROS17/2.8 cells were treated with pervanadate (100 mM) for 30 min, and InsR was immunoprecipated. The immune complex was then incubated at 30 C in the presence of 1 mg of recombinant GST, GST-PTP, or GST-PTPDA for indicated times. Phosphorylation of InsR was visualized by western blot. In in vivo trapping experiments, MG-63 or ROS17/2.8 cells were transfected with FLAG-tagged expression vector, and complexes were immunoprecipitated using anti-FLAG antibodies.
Cell Culture
Human osteoblastic cells hFOB 1.19, Saos-2 (ATCC) or mouse primary osteoblasts were transfected with siRNA pools (On-target, Dharmacon) according to the manufacturer instructions. InsR +/+ and InsR À/À osteoblasts were generated ex vivo by infecting InsR flox/flox with either GFP-or Cre-expressing adenovirus (University of Iowa). Bone marrow progenitor cells and osteoblasts cocultures were performed as previously described (Takahashi et al., 1988) . In vitro resorption activity of osteoclasts was measured using BD BioCoat Osteologic Bone Cell Culture System.
Mass Spectrometry
Synthetic carboxylated osteocalcin (Bio-Synthesis Inc.) was incubated at 37 C in pH 7.5 or pH 4.5 0.1 M phosphate buffer for 2 weeks. Mass spectrometry was run using Bruker Apex 9.4T Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometer and Daltonics DataAnalysis software (v. 3.4) for analysis. Comparative quantification between carboxylated and undercarboxylated osteocalcin were made based on exact mass measurements and fit of isotopic peaks to that of theoretical isotopic patterns (SNAP2 algorithm).
Statistics
Results are given as means ± standard errors of the mean except in human studies in which standard deviations were used. Statistical analyses were performed using unpaired, two-tailed Student's t test for comparison between two groups and One-way ANOVA test for more than two groups comparison. For GTT, ITT, and GSIS, we performed two-way mixed designed ANOVA and calculated Area Under the Curve (AUC) followed by student's t test or One-way ANOVA. For all experiments (*p or #p) % 0.05, (**p or ##p) % 0.01, ***p % 0.001.
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